Update on adult immunizations

Journal of the American Board of Family Medicine

Volumn 25, Issue 4, 2012, Pages 496-510

  Wolfe, Robert M ^a,b  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Adult; Immunization; Prevention; Review; Vaccination

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; TETANUS TOXOID; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE;

ADULT DISEASE; CHICKENPOX; DIABETIC PATIENT; DIPHTHERIA; DRUG EFFICACY; DRUG INDICATION; HEPATITIS A; HEPATITIS B; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; INFECTION RISK; INFECTION SENSITIVITY; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; MEASLES; MENINGOCOCCOSIS; MUMPS; NONHUMAN; PERTUSSIS; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PREGNANT WOMAN; REVIEW; RUBELLA; SECOND TRIMESTER PREGNANCY; TETANUS; THIRD TRIMESTER PREGNANCY; UNITED STATES; UTERINE CERVIX CANCER;

ADULT; BACTERIAL VACCINES; FEMALE; GUIDELINES AS TOPIC; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; MALE; MIDDLE AGED; UNITED STATES; VIRAL VACCINES; YOUNG ADULT;

EID: 84863708848     PISSN: 15572625     EISSN: 15587118     Source Type: Journal    
DOI: 10.3122/jabfm.2012.04.100274     Document Type: Review

References (55)

1. CDC. Adult vaccination coverage-United States, 2010. MMWR Morb Mortal Wkly Rep 2012;61:66-72.
2. Infectious Diseases Society of America, Robert Wood Johnson Foundation, Trust for America's Health. Adult immunization: shots to save lives. Washington, DC: Trust for America's Health, the Infectious Diseases Society of America, and the Robert Wood Johnson Foundation; 2010. Available from: http:// healthyamericans.org/report/73/adultimmunization-2010. Accessed May 22, 2012.
3. CDC. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60:1128-32.
4. Rhorer J, Ambrose CS, Dickinson S, et al. Efficacy of live attenuated influenza vaccine in children: A metaanalysis of nine randomized clinical trials. Vaccine 2009;27:1101-10.
5. Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009;361:1260-7.
6. Tosh PK, Boyce TG, Poland GA. Flu myths: dispelling the myths associated with live attenuated influenza vaccine. Mayo Clin Proc 2008;83:77-84.
7. Fluzone [package insert]. Swiftwater, PA: Sanofi Pasteur Inc.; 2011.
8. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. Wkly Epidemiol Rec 2007;82:93-104.
9. Centers for Disease Control and Prevention. Pneumococcal disease. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J, eds. 12th ed., second printing. Washington DC: Public Health Foundation; 2012:233-48. Available from: http://www.cdc.gov/vaccines/pubs/ pinkbook/pneumo.html. Accessed May 22, 2012.
10. World Health Organization. 23-Valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec 2008;83:373-84.
11. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis 2010;10:83-92.
12. Vila-Córcoles A. Vaccinate your child and save its grandparents from a heart attack? Current perspectives in antipneumococcal vaccination. J Intern Med 2009;266:432-44.
13. Hung IFN, Leung AYM, Chu DWS, et al. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin Infect Dis 2010;51:1007-16.
14. Nichol KL. Pneumococcal vaccination and revaccination in the elderly population. J Infect Dis 2010;201:659-61.
15. Musher DM, Manoff SB, McFetridge RD, et al. Antibody persistence 10 years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults. Hum Vaccin 2011;7:919-28.
16. Hammitt LL, Bulkow LR, Singleton RJ, et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine 2011;29:2287-95.
17. Musher DM, Sampath R, Rodriguez-Barradas MC. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? Clin Infect Dis 2011;52:633-40.
18. Specifications Manual, Version 4.0c. Discharges 01/01/2012 to 06/30/2012. Available from: http://www.qualitynet.org/dcs/ContentServer?c= Page&pagename=QnetPublic%2FPage%2FQnetTier4&cid=1228767363466. Accessed May 22, 2012.
19. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1-30; quiz CE2-4.
20. Gnann JW, Whitley RJ. Herpes zoster. N Engl J Med 2002;347:340-6. (Pubitemid 34815357)
21. Li Q, Chen N, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009;(2):CD006866.
22. Centers for Disease Control and Prevention. Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep 2011;60:1528.
23. Singh A, Englund K. Q: Who should receive the shingles vaccine? Cleve Clin J Med 2009;76:45-8.
24. Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011;305:160-6.
25. MacIntyre C, Egerton T, McCaughey M, et al. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old. Abstract presented at: ICAAC/IDSA 2008 Joint Meeting, October 25-28, 2008, Washington, DC.
26. Centers for Disease Control and Prevention. Vaccines and preventable diseases: herpes zoster vaccination for health care professionals. 2011. Available at: http://www.cdc.gov/vaccines/vpd-vac/shingles/hcp-vaccination.htm. Accessed February 3, 2012.
27. Tseng HF, Smith N, Sy LS, Jacobsen SJ. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine 2011;29:3628-32.
28. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56(RR-2):1-24.
29. Centers for Disease Control and Prevention. Human papillomavirus. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J, eds. 12th ed., second printing. Washington DC: Public Health Foundation; 2012: 139-50. Available from: http://www.cdc.gov/vaccines/pubs/ pinkbook/hpv.html. Accessed May 22, 2012.
30. D'Souza G, Dempsey A. The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med 2011;53(Suppl 1):S5-11.
31. Broomall E, Reynolds S, Jacobson R. Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus. Postgrad Med 2010;122:121-9.
32. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010;59:626-9.
33. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 2004;31:744-54. (Pubitemid 39602680)
34. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467-75. (Pubitemid 40270113)
35. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the united states. J Clin Oncol 2011;29:4294-301.
36. D'Souza G, Kreimer AR, Viscidi R, et al. Casecontrol study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-56. (Pubitemid 46740304)
37. Dufour X, Beby-Defaux A, Agius G, Lacau St Guily J. HPV and head and neck cancer. Eur Ann Otorhinolaryngol Head Neck Dis 2012;129:26-31.
38. Gillison ML, Broutian T, Pickard RKL, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012;307:693-703.
39. Gillison ML. Human papillomavirus-related diseases: oropharynx cancers and potential implications for adolescent HPV vaccination. J Adolesc Health 2008;43(4 Suppl):S52-60.
40. Cherry JD. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 2005;115:1422-7. (Pubitemid 43852794)
41. Centers for Disease Control and Prevention. Pertussis. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J, eds. 12th ed., second printing. Washington DC: Public Health Foundation; 2012:215-32. Available from: http://www.cdc.gov/vaccines/pubs/pinkbook/pert. html. Accessed May 22, 2012.
42. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005;24(5 Suppl):S58-61. (Pubitemid 40676539)
43. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60:1424-6.
44. Atkinson W, Kroger A. IAC Express 2010. Issue number 871: June 2, 2010. Ask the experts. Available from: http://www.immunize.org/express/issue871.asp. Accessed January 15, 2012.
45. Centers for Disease Control and Prevention. Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60(RR-7):1-45.
46. Centers for Disease Control and Prevention. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR Morb Mortal Wkly Rep 2009;58:1042-3.
47. Centers for Disease Control and Prevention. Updated recommendations for use of meningococcal conjugate vaccines-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2011;60:72-6.
48. Marin M, Güris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56(RR-4):1-40.
49. Centers for Disease Control and Prevention. Notice to readers: FDA approval of an alternate dosing schedule for a combined hepatitis A and B vaccine (Twinrix). MMWR Morb Mortal Wkly Rep 2007;56:1057.
50. Centers for Disease Control and Prevention. Update: prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2007;56:1080-4.
51. Centers for Disease Control and Prevention. Updated recommendations from the Advisory Committee on Immunization Practices (ACIP) for use of hepatitis A vaccine in close contacts of newly arriving international adoptees. MMWR Morb Mortal Wkly Rep 2009;58:1006-7.
52. Centers for Disease Control and Prevention. Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011;60:1709-11.
53. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part II: immunization of adults. MMWR Recomm Rep 2006; 55(RR-16):1-33; quiz CE1-4.
54. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWRRecomm Rep 1997;46(RR- 8):1-24. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00047135.htm. Accessed May 22, 2012.
55. Government of Canada PHAOC. Statement on the recommended use of herpes zoster vaccine: an Advisory Committee Statement-Canada Communicable Disease Report (CCDR). Vol. 0.35. ACS-1, Public Health Agency of Canada. Available at: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/10vol36/acs-1/index-eng.php. Accessed May 22, 2012.